Quantitative viral load testing is the World Health Organization-recommended monitoring tool for diagnosing and confirming the failure of antiretroviral therapy and is also the recommended approach to early infant diagnosis of HIV.
We recognize there are significant challenges limiting our partners’ investments in viral load and early infant diagnosis testing. Some of the challenges include high and variable costs for testing technologies, low utilization of machines and frequent test malfunctions. Expanding viral load and early infant diagnosis testing can be complex and requires, in addition to the cost of the products, significant investments in infrastructure, transport networks and people.
We established framework agreements with diagnostic manufacturers in 2015 with the aim of bringing more transparency and competition to the HIV viral load market.
Our procurement strategy focuses on both optimizing existing equipment and investments as well as supporting scale-up. The long-term goal is to achieve simple, transparent and affordable pricing with optimal contracting models for analyzers and/or reagents for both new and existing investments. We promote maintaining a sustainable, competitive market by:
Our interactive HIV Viral Load and Early Infant Diagnosis Selection and Procurement Information tool provides guidance and clarity for partners procuring these technologies:
The tool addresses high-level topics including country scenarios, programming and funding, request for proposal process and outcomes, platform/technology selection, pricing options and contracting options.
Additional resources are available below to download and access.